WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 27, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 19, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Thursday, November 2, 2023 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 29, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”)
Data Further Position ELAHERE to Become the New Standard of Care for Patients with FRα-Positive Platinum-Resistant Ovarian Cancer Findings to be Highlighted in Oral Presentation at ESGO Annual Congress WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 28, 2023-- ImmunoGen Inc.
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 18, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on September 18, 2023 , and in connection with the previously announced appointment of Ms.
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 18, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Lauren White has been appointed Senior Vice President and Chief Financial Officer.
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 5, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”)
ImmunoGen to Receive $34 Million 1 in Upfront and Near-Term Milestone Payments and is Eligible to Receive Potential Regulatory and Commercial Milestone Payments as well as Double-Digit Royalties Collaboration Further Supports Strategy to Bring ELAHERE to Eligible Patients with Folate Receptor Alpha
WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 1, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”)
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 31, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit , MD, Senior Vice President and Chief Medical Officer, is stepping down from her